Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

NCT01873833 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Insufficient accrual

Conditions

HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: capecitabine
DRUG: cyclophosphamide
DRUG: lapatinib ditosylate
BIOLOGICAL: trastuzumab
OTHER: laboratory biomarker analysis

Sponsor

University of Southern California

Collaborators

[object Object]